Recently, Epic Pharma, a wholly owned subsidiary of Humanwell Pharmaceutical Group, received approval of U.S. Food and Drug Administration (FDA) for gabapentin capsules.

　　Gabapentin capsules can be used for the treatment of postherpetic neuralgia and auxiliary therapy of partial epilepsy. Epic Pharma submitted gabapentin ANDA application in 2014, with a rough investment of 1.2 million dollars in research and development. According to the data shown in Menet, the 2016 total sales of gabapentin capsule in the American market were about 200 million dollars.

　　Humanwell Pharmaceutical Group made the complete acquisition in 2016. Its subsidiary corporation, located in New York, America, is a pharmaceutical enterprise with a combination of research and development, production and sales. The company has passed the FDA and DEA audit and has controlled drugs production qualification and mature sales channels, whose main product formulations include tablets, capsules and powder. (Correspondent Chen Ran)